Department of Hematology,Hospital Universitario de Gran Canaria Dr.Negrín,Las Palmas de Gran Canaria 35019,Spain;
Biomarkers; Tyrosine kinase inhibitors; Treatment discontinuation; Molecular monitoring; Duration of therapy; Leukemia; Myelogenous; Chronic; BCR-ABL positive;